chronic lymphoproliferative disodersoverall survivalnon-Hodgkin's lymphomaHodgkin lymphomachronic lymphocytic leukemiamultiple myelomatarget therapyхронические лимфопролиферативные заболеванияобщая выживаемостьнеходжкинские лимфомылимфома Ходжкинахронический лимфолейкозмножественная миеломатаргетная терапия1.1. Fowler N., Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program 2013;2013:553.60.Fowler N., Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program 2013;2013:553.60.2.2. Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Под ред. М.И. Давыдова, Е.М. Аксель. Вестник РОНЦ им. Н.Н. Блохина РАМН 2011;22(3) (прил. 1). [Malignancies statistics in Russia and CIS countries in 2009. Eds.: Davydov M.I., Aksel E.M. Vestnik RONC RAMN = Bulletin of N.N. Blokhin Russian Cancer Research Center 2011;22(3) (Suppl.1). (In Russ.)].Статистика злокачественных новообразований в России и странах СНГ в 2009 г. Под ред. М.И. Давыдова, Е.М. Аксель. Вестник РОНЦ им. Н.Н. Блохина РАМН 2011;22(3) (прил. 1). [Malignancies statistics in Russia and CIS countries in 2009. Eds.: Davydov M.I., Aksel E.M. Vestnik RONC RAMN = Bulletin of N.N. Blokhin Russian Cancer Research Center 2011;22(3) (Suppl.1). (In Russ.)].3.3. Siegel R., Ma J., Zou Z., Jemal A. Cancer Statistics, 2014. CA Cancer J Clin 2014;64(1):9.29.Siegel R., Ma J., Zou Z., Jemal A. Cancer Statistics, 2014. CA Cancer J Clin 2014;64(1):9.29.4.4. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013;122(23):3723.34.Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013;122(23):3723.34.5.5. Mikhael J.R., Dingli D., Roy V. et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART). Consensus Guidelines 2013. Mayo Clin Proc 2013;88:360.76.Mikhael J.R., Dingli D., Roy V. et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART). Consensus Guidelines 2013. Mayo Clin Proc 2013;88:360.76.6.6. Rajkumar S.V., Dimopoulos M.A., Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538.48.Rajkumar S.V., Dimopoulos M.A., Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538.48.7.7. Zhou Z., Sehn L.H., Rademaker A.W. et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the ituximab era. Blood 2014;123(6):837.42.Zhou Z., Sehn L.H., Rademaker A.W. et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the ituximab era. Blood 2014;123(6):837.42.8.8. Ludwig H., Miguel J.S., Dimopoulos M.A. et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014;28(5):981.92.Ludwig H., Miguel J.S., Dimopoulos M.A. et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia 2014;28(5):981.92.9.9. Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop n Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446.56.Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop n Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446.56.10.10. Abramson J.S., Zelenetz A.D. Recent advances in the treatment of non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2013;11(5 Suppl):671.5.Abramson J.S., Zelenetz A.D. Recent advances in the treatment of non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2013;11(5 Suppl):671.5.11.11. Cheson B.D., Fisher R.I., Barrington S.F. et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. JCO 2014;32(27):3059.67.Cheson B.D., Fisher R.I., Barrington S.F. et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. JCO 2014;32(27):3059.67.12.12. Diefenbach C., Steidl C. New strategies in Hodgkin lymphoma: better risk profiling and novel treatments. Clin Cancer Res 2013;19(11):2797.803.Diefenbach C., Steidl C. New strategies in Hodgkin lymphoma: better risk profiling and novel treatments. Clin Cancer Res 2013;19(11):2797.803.13.13. Eichenauer D.A., Engert A., Andre M. et al. Hodgkin's Lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii70.5.Eichenauer D.A., Engert A., Andre M. et al. Hodgkin's Lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25 Suppl 3:iii70.5.14.14. Гринхальх Т. Основы доказательной медицины. Пер. с англ. М.: ГЭОТАР-Медиа, 2004. 240 с. [Greenhalgh T. The Basics of Evidence Based Medicine. Trans. rom English. M.: GEOTAR-MED, 2004. 240 pp. (In Russ.)].Гринхальх Т. Основы доказательной медицины. Пер. с англ. М.: ГЭОТАР-Медиа, 2004. 240 с. [Greenhalgh T. The Basics of Evidence Based Medicine. Trans. rom English. M.: GEOTAR-MED, 2004. 240 pp. (In Russ.)].15.15. Власов В.В. Введение в доказательную медицину. М.: Медиа Сфера, 2001. 392 с. [Vlasov V.V. Introduction to evidence-based medicine. M.: Media Sfera, 2001. 392 pp. (In Russ.)].Власов В.В. Введение в доказательную медицину. М.: Медиа Сфера, 2001. 392 с. [Vlasov V.V. Introduction to evidence-based medicine. M.: Media Sfera, 2001. 392 pp. (In Russ.)].16.16. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиа Сфера, 2002. 312 с. Rebrova O.Yu. Statistical analysis of medical data. Application of software package STATISTICA. M.: Media Sfera, 2002. 312 pp. (In Russ).].Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: Медиа Сфера, 2002. 312 с. Rebrova O.Yu. Statistical analysis of medical data. Application of software package STATISTICA. M.: Media Sfera, 2002. 312 pp. (In Russ).].17.17. Swerdlow S.H., Campo E., Harris N.L. et al. (eds.). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, Lyon, 2008. 439 p.Swerdlow S.H., Campo E., Harris N.L. et al. (eds.). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, Lyon, 2008. 439 p.18.18. Criteria or the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. International Myeloma Working Group. Br J Haematol 2003;121(5):749.57.Criteria or the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. International Myeloma Working Group. Br J Haematol 2003;121(5):749.57.19.19. Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23(1):3.9.Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23(1):3.9.20.20. Greipp P.R., San Miguel J., Durie B.G. et al. International staging system for multiple myeloma. J Clin Oncol 2005;23(15):3412.20.Greipp P.R., San Miguel J., Durie B.G. et al. International staging system for multiple myeloma. J Clin Oncol 2005;23(15):3412.20.21.21. Rai K.R., Savitsky A., Cronkite E.P. et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219.34.Rai K.R., Savitsky A., Cronkite E.P. et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219.34.22.22. Cheson B.D., Pfistner B., Juweid M.E. et al.; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579.86.Cheson B.D., Pfistner B., Juweid M.E. et al.; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579.86.23.23. Durie B.G., Harousseau J.L., Miguel J.S. et al.; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006;20(9):1467.73.Durie B.G., Harousseau J.L., Miguel J.S. et al.; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 2006;20(9):1467.73.24.24. Rajkumar S.V., Harousseau J.L., Durie B. et al.; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of linical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117(18):4691.5.Rajkumar S.V., Harousseau J.L., Durie B. et al.; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of linical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117(18):4691.5.25.25. «О совершенствовании системы Государственного ракового регистра». Приказ МЗ РФ № 135 от 19 апреля 1999 г. 172 с. [“On Improving of the State ancer Registry”. Order of the Ministry of Health of Russian Federation № 135; 19 April 1999. 172 pp. (In Russ.)].«О совершенствовании системы Государственного ракового регистра». Приказ МЗ РФ № 135 от 19 апреля 1999 г. 172 с. [“On Improving of the State ancer Registry”. Order of the Ministry of Health of Russian Federation № 135; 19 April 1999. 172 pp. (In Russ.)].26.26. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.81.Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.81.27.27. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non- Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 993;329(14):987.94.A predictive model for aggressive non-Hodgkin's lymphoma. The International Non- Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 993;329(14):987.94.28.28. http://seer.cancer.gov/statfacts/html/nhl.html.http://seer.cancer.gov/statfacts/html/nhl.html.29.29. Oliva S., Caltagirone S., Passera R. et al. Revised international staging system (R-ISS): a new and simple prognostic assessment for multiple myeloma. EHA 2014 ongress Milan, abstr. S1289.Oliva S., Caltagirone S., Passera R. et al. Revised international staging system (R-ISS): a new and simple prognostic assessment for multiple myeloma. EHA 2014 ongress Milan, abstr. S1289.30.30. http://seer.cancer.gov/statfacts/html/mulmy.html.http://seer.cancer.gov/statfacts/html/mulmy.html.31.31. Kumar S.K., Dispenzieri A., Lacy M.Q. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28(5):1122–8.Kumar S.K., Dispenzieri A., Lacy M.Q. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28(5):1122–8.32.32. Pflug N., Bahlo J., Shanafelt T.D. et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 014;124(1):49– 2.Pflug N., Bahlo J., Shanafelt T.D. et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 014;124(1):49– 2.33.33. Eichhorst B., Fink A., Busch R. et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and ituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a planned interim analysis of the LL10 trial, an international, randomized study of The German CLL Study Group (GCLLSG). rogram and abstracts of the 55th American Society of Hematology Annual eeting and Exposition; December 7–10, 2013; New Orleans, Louisiana. Abstr. 526.Eichhorst B., Fink A., Busch R. et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and ituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a planned interim analysis of the LL10 trial, an international, randomized study of The German CLL Study Group (GCLLSG). rogram and abstracts of the 55th American Society of Hematology Annual eeting and Exposition; December 7–10, 2013; New Orleans, Louisiana. Abstr. 526.34.34. Goede V., Fischer K., Busch R. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370(12):1101–10. 35. urger J.A., Keating M.J., Wierda W.G. et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, hase 2 study. Lancet Oncol 2014;15(10):1090–9.Goede V., Fischer K., Busch R. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370(12):1101–10. 35. urger J.A., Keating M.J., Wierda W.G. et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, hase 2 study. Lancet Oncol 2014;15(10):1090–9.35.36. Furman R.R., Sharman J.P., Coutre S.E. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370(11):997–1007.Furman R.R., Sharman J.P., Coutre S.E. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370(11):997–1007.36.37. http://seer.cancer.gov/statfacts/html/hodg. html.http://seer.cancer.gov/statfacts/html/hodg. html.37.38. Younes A., Gopal A.K., Smith S.E. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30(18):2183–9.Younes A., Gopal A.K., Smith S.E. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30(18):2183–9.38.39. Niraula S., Seruga B., Ocana A. et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 2012;30(24):3012–9Niraula S., Seruga B., Ocana A. et al. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 2012;30(24):3012–939.40. Поп В.П., Кучма Ю.М. Резистентность к индукционной терапии ухудшает общую выживаемость больных с хроническими лимфопролиферативными або- леваниями. Актуальные проблемы оказания специализированной медицинской помощи в условиях стационара и применение стационарозамещающих технологий. Тезисы докладов научно-практической конференции. М.: ГВКГ им. Н.Н. Бурденко, 2009. С. 204. [Pop V.P., Kuchma u.M. esistance to induction therapy worsens the overall survival of patients with chronic lymphoproliferative disorders. Abstracts book of Russian Conference “Actual problems of specialized medical care in a hospital and use of hospital-replacing echnologies”. M.: Burdenko Main Military Clinical Hospital, 2009, p. 204 (In Russ.)].Поп В.П., Кучма Ю.М. Резистентность к индукционной терапии ухудшает общую выживаемость больных с хроническими лимфопролиферативными або- леваниями. Актуальные проблемы оказания специализированной медицинской помощи в условиях стационара и применение стационарозамещающих технологий. Тезисы докладов научно-практической конференции. М.: ГВКГ им. Н.Н. Бурденко, 2009. С. 204. [Pop V.P., Kuchma u.M. esistance to induction therapy worsens the overall survival of patients with chronic lymphoproliferative disorders. Abstracts book of Russian Conference “Actual problems of specialized medical care in a hospital and use of hospital-replacing echnologies”. M.: Burdenko Main Military Clinical Hospital, 2009, p. 204 (In Russ.)].40.41. Wildes T.M., Goede V., Hamlin P. Personalizing therapy for older adults with lymphoid malignancies: options and obstacles. Am Soc Clin Oncol Educ Book 2014:e240–8.Wildes T.M., Goede V., Hamlin P. Personalizing therapy for older adults with lymphoid malignancies: options and obstacles. Am Soc Clin Oncol Educ Book 2014:e240–8.41.42. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под руководством профессора И.В. оддубной, профессора В.Г. Савченко. М.: ММА МедиаМедика, 2014. 128 с. [Russian clinical guidelines for diagnosis and treatment of lymphoproliferative iseases. Eds.: prof. Poddubnaya I.V., prof. Savchenko V.G. M.: MMA MediaMedica, 2014. 128 pp. (In Russ.)].Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под руководством профессора И.В. оддубной, профессора В.Г. Савченко. М.: ММА МедиаМедика, 2014. 128 с. [Russian clinical guidelines for diagnosis and treatment of lymphoproliferative iseases. Eds.: prof. Poddubnaya I.V., prof. Savchenko V.G. M.: MMA MediaMedica, 2014. 128 pp. (In Russ.)].42.43. Национальное руководство по гематологии. Под ред. О.А. Рукавицына (в печати). [Hematology National Guidance. Ed.: Rukavitsyn O.A. (in press). (In uss)].Национальное руководство по гематологии. Под ред. О.А. Рукавицына (в печати). [Hematology National Guidance. Ed.: Rukavitsyn O.A. (in press). (In uss)].